SCHEMBL20179151

SCHEMBL20179151

CCOC(=O)c1ccc(CC(CCC(=O)NOCc2ccc(OC(C)=O)cc2)C(=O)OCC)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.44
EPHX2 P34913 9/20 0.41
PPARG P37231 6/20 0.41
PPARA Q07869 2/20 0.41
HTT P42858 1/20 0.39
MAPT P10636 1/20 0.39
PRSS1 P07477 1/20 0.38
ACR P10323 1/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 1/20 0.37
SLC22A2 O15244 1/20 0.37
TMPRSS2 O15393 1/20 0.37
F2 P00734 1/20 0.37
F10 P00742 1/20 0.37
PLG P00747 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20179205 0.93 FOLH1 (0.52) FOLH1EPHX2PPARGPPARAHTT
SCHEMBL20168306 0.93 FOLH1 (0.42) FOLH1EPHX2PPARGPPARAHTT
SCHEMBL21577995 0.89 HTT (0.39) FOLH1PPARGHTTPRSS1ACR
SCHEMBL24023462 0.86 FOLH1 (0.39) FOLH1EPHX2PPARGPPARAMAPT
SCHEMBL20179243 0.85 FOLH1 (0.42) FOLH1NPC1LMNA
SCHEMBL20179203 0.82 KMT2A (0.47) EPHX2HTTMAPTPRSS1ACR
SCHEMBL20168729 0.82 FOLH1 (0.62) FOLH1EPHX2PPARGPPARAPRSS1
SCHEMBL20168291 0.82 FOLH1 (0.50) FOLH1NPC1LMNASMN1; SMN2
SCHEMBL20179200 0.80 FOLH1 (0.51) FOLH1PPARGPPARAMAPTPRSS1
SCHEMBL20179187 0.80 FOLH1 (0.45) FOLH1EPHX2PPARGPPARAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSTY (US) 2024-01-09 US disclosed
WO-2023154939-A2 GCPII INHIBITION FOR THE TREATMENT OF SARCOPENIA AND AGING THE JOHNS HOPKINS UNIVERSITY (US) 2023-08-17 WO disclosed
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2021-11-18 US disclosed
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-13 US disclosed
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY 2019-11-21 US disclosed
WO-2018094334-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS THE JOHNS HOPKINS UNIVERSITY (US) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352255-A1 NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS GPI, TPI1, HPGDS FOLH1 10/4885EPHX2 1026/4885PPARG 1130/4885
US-20210355079-A1 PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS TPI1, HPGDS, GPI FOLH1 39/4885EPHX2 1624/4885PPARG 707/4885
US-11059775-B2 Prodrug compositions and utility of hydroxamate-based GCPII inhibitors GLS, HPGDS, GPI FOLH1 15/4885EPHX2 1037/4885PPARG 986/4885
US-11866394-B2 Prodrugs of hydroxamate-based GCPII inhibitors TPI1, HPGDS, GPI FOLH1 39/4885EPHX2 1624/4885PPARG 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.